
    
      The primary objective of this study is to evaluate the efficacy of ixmyelocel-T compared to
      placebo (vehicle control) on the average per patient number of all-cause deaths,
      cardiovascular hospital admissions, and unplanned outpatient or emergency department visits
      to treat acute decompensated heart failure, over the 12 months following administration of
      investigational product (IP).
    
  